Kenneth Hoberman

Kenneth Hoberman

Director de Operaciones en STEMLINE THERAPEUTICS, INC. .

Fortuna: 19 M $ al 30/09/2026

61 años
Health Technology
Consumer Services
Commercial Services

Perfil

Mr. Kenneth Hoberman is an Independent Director at Nuvectis Pharma, Inc., an Independent Director at TG Therapeutics, Inc. and a Chief Operating Officer at Stemline Therapeutics, Inc. He is on the Board of Directors at Lirum Therapeutics, Inc., Nuvectis Pharma, Inc. and TG Therapeutics, Inc. Mr. Hoberman was previously employed as a Vice President-Corporate & Business Development by Keryx Biopharmaceuticals, Inc. He received his undergraduate degree from Boston University.

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
11/06/2026 279.653 ( 0,18 % ) 16 M $ 30/09/2026
11/06/2026 168.140 ( 0,52 % ) 4 M $ 30/09/2026

Cargos activos de Kenneth Hoberman

EmpresasCargoInicio
STEMLINE THERAPEUTICS, INC. Director de Operaciones 01/01/2013
TG THERAPEUTICS, INC. Director/Miembro de la Junta 15/12/2014
NUVECTIS PHARMA, INC. Director/Miembro de la Junta 01/07/2021
LIRUM THERAPEUTICS, INC. Director/Miembro de la Junta 01/11/2021

Antiguos cargos conocidos de Kenneth Hoberman.

EmpresasCargoFin
KERYX BIOPHARMACEUTICALS Corporate Officer/Principal 01/01/2012
Ver el detalle de la experiencia de Kenneth Hoberman.

Formación de Kenneth Hoberman.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

51

Relaciones de 1er grado

6

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas6

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Commercial Services

  1. Bolsa de valores
  2. Insiders
  3. Kenneth Hoberman